Kamada (KMDA) Competitors $5.87 +0.02 (+0.34%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends KMDA vs. FULC, PRTK, BYSI, UBX, CTIC, OCUL, RCUS, SPRY, GYRE, and ARQTShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Fulcrum Therapeutics (FULC), Paratek Pharmaceuticals (PRTK), BeyondSpring (BYSI), Unity Biotechnology (UBX), CTI BioPharma (CTIC), Ocular Therapeutix (OCUL), Arcus Biosciences (RCUS), ARS Pharmaceuticals (SPRY), Gyre Therapeutics (GYRE), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "medical" sector. Kamada vs. Fulcrum Therapeutics Paratek Pharmaceuticals BeyondSpring Unity Biotechnology CTI BioPharma Ocular Therapeutix Arcus Biosciences ARS Pharmaceuticals Gyre Therapeutics Arcutis Biotherapeutics Fulcrum Therapeutics (NASDAQ:FULC) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk. Do institutionals and insiders believe in FULC or KMDA? 89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 4.1% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer FULC or KMDA? Fulcrum Therapeutics currently has a consensus price target of $9.33, indicating a potential upside of 187.18%. Kamada has a consensus price target of $14.50, indicating a potential upside of 147.02%. Given Fulcrum Therapeutics' higher probable upside, equities research analysts clearly believe Fulcrum Therapeutics is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20Kamada 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor FULC or KMDA? Kamada received 223 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 65.91% of users gave Kamada an outperform vote while only 61.25% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformFulcrum TherapeuticsOutperform Votes9861.25% Underperform Votes6238.75% KamadaOutperform Votes32165.91% Underperform Votes16634.09% Which has preferable earnings & valuation, FULC or KMDA? Kamada has higher revenue and earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80.87M2.17-$97.33M-$0.31-10.48Kamada$142.52M2.37$8.28M$0.2820.96 Is FULC or KMDA more profitable? Kamada has a net margin of 9.92% compared to Fulcrum Therapeutics' net margin of 0.00%. Kamada's return on equity of 6.30% beat Fulcrum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -7.31% -6.74% Kamada 9.92%6.30%4.49% Does the media refer more to FULC or KMDA? In the previous week, Fulcrum Therapeutics and Fulcrum Therapeutics both had 7 articles in the media. Fulcrum Therapeutics' average media sentiment score of 0.73 beat Kamada's score of -0.29 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, FULC or KMDA? Fulcrum Therapeutics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. SummaryKamada beats Fulcrum Therapeutics on 12 of the 17 factors compared between the two stocks. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$337.41M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio20.9611.10105.1417.83Price / Sales2.37362.031,233.15158.41Price / Cash13.8652.5940.4136.29Price / Book1.3210.377.096.50Net Income$8.28M$153.60M$119.65M$226.22M7 Day Performance1.03%4.60%2.25%4.03%1 Month Performance9.93%-6.29%-2.33%4.92%1 Year Performance23.59%33.41%33.98%29.30% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada3.8019 of 5 stars$5.87+0.3%$14.50+147.0%+23.6%$337.41M$142.52M20.96360FULCFulcrum Therapeutics3.5831 of 5 stars$2.97-0.7%$9.33+214.3%-28.6%$160.20M$2.81M-9.58100PRTKParatek PharmaceuticalsN/A$2.23+1.8%N/A+0.0%$127.82M$160.27M-2.03268Analyst ForecastHigh Trading VolumeBYSIBeyondSpringN/A$1.73+1.2%N/A+91.2%$67.52M$1.75M0.0080UBXUnity Biotechnology3.523 of 5 stars$1.17flat$8.00+583.8%-43.6%$19.71M$240,000.00-0.8960CTICCTI BioPharmaN/A$9.09flatN/AN/A$1.20B$53M-15.67127Analyst ForecastOCULOcular Therapeutix3.6818 of 5 stars$8.52-3.0%$16.71+96.2%+296.0%$1.34B$58.44M-6.45267RCUSArcus Biosciences2.7564 of 5 stars$14.30-2.2%$34.00+137.8%+6.0%$1.31B$117M-4.54500SPRYARS Pharmaceuticals2.5899 of 5 stars$13.42-1.0%$24.00+78.9%+196.0%$1.30B$30,000.00-26.3090GYREGyre Therapeutics0.4886 of 5 stars$11.75-9.0%N/A-29.9%$1.21B$105.03M0.0040Gap UpARQTArcutis Biotherapeutics1.7743 of 5 stars$10.31+1.3%$15.50+50.3%+439.4%$1.21B$59.61M-5.84150 Related Companies and Tools Related Companies Fulcrum Therapeutics Alternatives Paratek Pharmaceuticals Alternatives BeyondSpring Alternatives Unity Biotechnology Alternatives CTI BioPharma Alternatives Ocular Therapeutix Alternatives Arcus Biosciences Alternatives ARS Pharmaceuticals Alternatives Gyre Therapeutics Alternatives Arcutis Biotherapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KMDA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KMDA Stock Alerts